RBC Capital analyst Randall Stanicky noted that Flexion Therapeutics' Phase IIb trial of FX006 for osteoarthritis knee pain missed its primary week-12 endpoint, but he believes that was due to a "statistical anomaly" and that clinical path and timing for the drug is unchanged. Stanicky, who reported that the company's management said it believes the overall strength of the data will be sufficient for FDA acceptance, said a selloff in the stock creates an opportunity to buy. The analyst maintains his Outperform rating and $44 price target on Flexion shares, which are down more than 25% to $21.55 in pre-market trading.